Brooks Laboratories Limited (BROOKS) - Total Liabilities
Based on the latest financial reports, Brooks Laboratories Limited (BROOKS) has total liabilities worth Rs242.82 Million INR (≈ $2.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Brooks Laboratories Limited (BROOKS) investment intensity to see how much of total assets are deployed in long-term investments.
Brooks Laboratories Limited - Total Liabilities Trend (2007–2025)
This chart illustrates how Brooks Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Brooks Laboratories Limited.
Brooks Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Brooks Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TG Metals Ltd
AU:TG6
|
Australia | AU$1.42 Million |
|
Biofrontera Inc
NASDAQ:BFRI
|
USA | $18.11 Million |
|
Shreyans Industries Limited
NSE:SHREYANIND
|
India | Rs2.07 Billion |
|
Botala Energy Ltd
AU:BTE
|
Australia | AU$2.47 Million |
|
ReWalk Robotics Ltd
NASDAQ:LFWD
|
USA | $22.78 Million |
|
Genius Group Ltd
NYSE MKT:GNS
|
USA | $17.19 Million |
|
Aqua Corporation Public Company Limited
BK:AQUA
|
Thailand | ฿3.40 Billion |
|
Sephaku Holdings Ltd
JSE:SEP
|
South Africa | ZAC328.05 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Brooks Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BROOKS equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Brooks Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Brooks Laboratories Limited (2007–2025)
The table below shows the annual total liabilities of Brooks Laboratories Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs255.90 Million ≈ $2.77 Million |
+2.94% |
| 2024-03-31 | Rs248.60 Million ≈ $2.69 Million |
-30.25% |
| 2023-03-31 | Rs356.44 Million ≈ $3.85 Million |
-42.13% |
| 2022-03-31 | Rs615.91 Million ≈ $6.66 Million |
-25.73% |
| 2021-03-31 | Rs829.29 Million ≈ $8.97 Million |
+39.50% |
| 2020-03-31 | Rs594.48 Million ≈ $6.43 Million |
-5.34% |
| 2019-03-31 | Rs628.00 Million ≈ $6.79 Million |
+7.92% |
| 2018-03-31 | Rs581.92 Million ≈ $6.29 Million |
+48.89% |
| 2017-03-31 | Rs390.85 Million ≈ $4.23 Million |
+28.20% |
| 2016-03-31 | Rs304.87 Million ≈ $3.30 Million |
+28.49% |
| 2015-03-31 | Rs237.28 Million ≈ $2.57 Million |
-15.70% |
| 2014-03-31 | Rs281.47 Million ≈ $3.04 Million |
+7.22% |
| 2013-03-31 | Rs262.53 Million ≈ $2.84 Million |
+80.56% |
| 2012-03-31 | Rs145.40 Million ≈ $1.57 Million |
-32.17% |
| 2011-03-31 | Rs214.36 Million ≈ $2.32 Million |
-9.22% |
| 2010-03-31 | Rs236.15 Million ≈ $2.55 Million |
+0.14% |
| 2009-03-31 | Rs235.82 Million ≈ $2.55 Million |
+15.20% |
| 2008-03-31 | Rs204.70 Million ≈ $2.21 Million |
+54.85% |
| 2007-03-31 | Rs132.20 Million ≈ $1.43 Million |
-- |
About Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more